Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
In this Form 4, Natera director and co-founder Sheena Jonathan reported sales totaling 6,070 shares of Natera common stock: 3,070 shares on 08/08/2025 and 3,000 shares on 08/11/2025. The filing lists weighted-average prices for the 08/08 sales roughly in the mid-$156 to mid-$164 range and for the 08/11 sales roughly in the low-$150 to mid-$156 range. Footnotes state the 08/08 sales were executed under a Rule 10b5-1 plan adopted December 11, 2024, and the 08/11 sales were executed under a separate Rule 10b5-1 plan adopted June 7, 2024.
Following these transactions the reporting person retained 242,252 shares reported as directly owned and reported indirect trust holdings associated with Caraluna trusts in the ~34,282–35,662 share range across the trust entries. No derivative securities were reported.
Insider Form 4 filing — Natera, Inc. (NTRA)
On 08/01/2025, Solomon Moshkevich (President, Clinical Diagnostics; officer) reported three sales of Natera common stock effected pursuant to a Rule 10b5-1 trading plan adopted on 11/26/2024. The reported dispositions were 1,574 shares at a weighted-average price of $132.4528 (range $131.9350–$132.78), 1,326 shares at $133.3097 (range $132.96–$133.80), and 100 shares at $134.08.
Post-transaction beneficial ownership: reported as 124,485; 123,159; and 123,059 shares respectively. The Form was signed by an attorney-in-fact on 08/05/2025.
Natera, Inc. (NTRA) filed a Form 144 indicating that insider Gail Marcus intends to sell up to 2,496 common shares through Merrill Lynch on or after 1 Aug 2025. The proposed sale is valued at $332,394.72, based on the market price at the time of filing. Natera has 136.55 million shares outstanding, so the planned sale equals <0.01 % of the float.
The shares were acquired via equity-compensation grants on 9 Jun 2024 (2,374 sh) and 26 Jul 2024 (122 sh). Marcus has already sold 12,299 shares over the past three months, generating gross proceeds of ≈$1.98 million (4,000 sh on 1 May 2025, 4,000 sh on 10 Jun 2025, 4,299 sh on 1 Jul 2025).
While the filing signals continued insider selling, the absolute volume remains immaterial relative to total shares and does not, by itself, imply a change in the company’s fundamentals.